Rutherford T - Search Results

1

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. English DP, et al. Among authors: rutherford t. Am J Obstet Gynecol. 2013 Nov;209(5):465.e1-9. doi: 10.1016/j.ajog.2013.07.020. Epub 2013 Jul 24. Am J Obstet Gynecol. 2013. PMID: 23891627

2

Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.

Turner BC, Knisely JP, Kacinski BM, Haffty BG, Gumbs AA, Roberts KB, Frank AH, Peschel RE, Rutherford TJ, Edraki B, Kohorn EI, Chambers SK, Schwartz PE, Wilson LD. Turner BC, et al. Among authors: rutherford tj. Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):77-84. doi: 10.1016/s0360-3016(97)00581-6. Int J Radiat Oncol Biol Phys. 1998. PMID: 9422561 Free article.

3

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Schwartz PE, et al. Among authors: rutherford tj. Gynecol Oncol. 1999 Jan;72(1):93-9. doi: 10.1006/gyno.1998.5236. Gynecol Oncol. 1999. PMID: 9889037 Free article.

4

Adenocarcinoma in situ of the cervix: management and outcome.

Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT. Azodi M, et al. Among authors: rutherford tj. Gynecol Oncol. 1999 Jun;73(3):348-53. doi: 10.1006/gyno.1999.5395. Gynecol Oncol. 1999. PMID: 10366458 Free article.

5

Absence of estrogen receptor-beta expression in metastatic ovarian cancer.

Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A, Mor G. Rutherford T, et al. Obstet Gynecol. 2000 Sep;96(3):417-21. doi: 10.1016/s0029-7844(00)00917-0. Obstet Gynecol. 2000. PMID: 10960636 Free article.

6

The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.

Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. Peng XY, et al. Among authors: rutherford t. Cancer Res. 2001 Jun 1;61(11):4405-13. Cancer Res. 2001. PMID: 11389068

7

Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure.

Yalcin OT, Rutherford TJ, Chambers SK, Chambers JT, Schwartz PE. Yalcin OT, et al. Among authors: rutherford tj. Eur J Obstet Gynecol Reprod Biol. 2003 Jan 10;106(1):64-8. doi: 10.1016/s0301-2115(02)00209-9. Eur J Obstet Gynecol Reprod Biol. 2003. PMID: 12475584 Clinical Trial.

8

A pilot study of topotecan in the treatment of serous carcinoma of the uterus.

Chambers JT, Rutherford TJ, Schwartz PE, Carcangiu ML, Chambers SK, Baker L. Chambers JT, et al. Among authors: rutherford tj. Int J Gynecol Cancer. 2003 Mar-Apr;13(2):216-22. doi: 10.1046/j.1525-1438.2003.13022.x. Int J Gynecol Cancer. 2003. PMID: 12657127 Clinical Trial.

9

Epithelial ovarian cancer cells secrete functional Fas ligand.

Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Abrahams VM, et al. Cancer Res. 2003 Sep 1;63(17):5573-81. Cancer Res. 2003. PMID: 14500397

10

Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.

Flick MB, O'Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, Schwartz P, Kacinski BM, Mor G. Flick MB, et al. Among authors: rutherford t. J Soc Gynecol Investig. 2004 May;11(4):252-9. doi: 10.1016/j.jsgi.2003.11.003. J Soc Gynecol Investig. 2004. PMID: 15120700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters